Hofheinz, R., Hegewisch-Becker, S., Kunzmann, V., Thuss-Patience, P., Fuchs, M., Homann, N., . . . Al-Batran, S. (2021). Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. International journal of cancer, 149(6), . https://doi.org/10.1002/ijc.33696
Chicago-Zitierstil (17. Ausg.)Hofheinz, Ralf-Dieter, et al. "Trastuzumab in Combination with 5-fluorouracil, Leucovorin, Oxaliplatin and Docetaxel as Perioperative Treatment for Patients with Human Epidermal Growth Factor Receptor 2-positive Locally Advanced Esophagogastric Adenocarcinoma: A Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group." International Journal of Cancer 149, no. 6 (2021). https://doi.org/10.1002/ijc.33696.
MLA-Zitierstil (9. Ausg.)Hofheinz, Ralf-Dieter, et al. "Trastuzumab in Combination with 5-fluorouracil, Leucovorin, Oxaliplatin and Docetaxel as Perioperative Treatment for Patients with Human Epidermal Growth Factor Receptor 2-positive Locally Advanced Esophagogastric Adenocarcinoma: A Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group." International Journal of Cancer, vol. 149, no. 6, 2021, https://doi.org/10.1002/ijc.33696.